All Stories

  1. A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era
  2. Impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis
  3. Factors associated with within-individual variability of lung function for people with cystic fibrosis: a longitudinal registry study
  4. Trajectories of early growth and subsequent lung function in cystic fibrosis: An observational study using UK and Canadian registry data
  5. A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era
  6. Response
  7. Future therapies for cystic fibrosis
  8. The Impact on Parents of Diagnosing PCD in Young Children
  9. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
  10. The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN
  11. Initiating home spirometry for children during the COVID-19 pandemic – A practical guide
  12. Exploring the nature of perceived treatment burden: a study to compare treatment burden measures in adults with cystic fibrosis
  13. Childhood bronchiectasis, so little is known
  14. Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study
  15. Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis
  16. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe
  17. COVID-19 vaccine prioritisation for people with cystic fibrosis
  18. Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study
  19. Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study
  20. Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis
  21. Learning to breathe with Tai Chi online - qualitative data from a randomized controlled feasibility study of patients with cystic fibrosis
  22. An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter
  23. Combination antifungal therapy for Scedosporium species in cystic fibrosis
  24. Registries and collaborative studies for primary ciliary dyskinesia in Europe
  25. Fair selection of participants in clinical trials: The challenge to push the envelope further
  26. Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from the UK CF registry
  27. Time trends in diagnostic testing for primary ciliary dyskinesia in Europe
  28. The prevalence, clinical status and genotype of cystic fibrosis patients living in Cuba using national registry data
  29. Seasonal fluctuation of lung function in cystic fibrosis: A national register-based study in two northern European populations
  30. Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials
  31. Identifying exceptional cystic fibrosis care services: combining statistical process control with focus groups
  32. The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis
  33. Investigating the effects of long-term dornase alfa use on lung function using registry data
  34. Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis
  35. Children and Adults Tai Chi Study (CF-CATS2): a randomised controlled feasibility study comparing internet-delivered with face-to-face Tai Chi lessons in cystic fibrosis
  36. Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales
  37. Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry
  38. Hypersensitivity reactions to intravenous antibiotics in cystic fibrosis
  39. Primary Ciliary Dyskinesia Due to Microtubular Defects is Associated with Worse Lung Clearance Index
  40. Pulmonary function deficits in newborn screened infants with cystic fibrosis managed with standard UK care are mild and transient
  41. Data Resource Profile: The UK Cystic Fibrosis Registry
  42. Recovery of baseline lung function after pulmonary exacerbation in children with primary ciliary dyskinesia
  43. Paranasal sinus pathogens in children with cystic fibrosis: Do they relate to lower respiratory tract pathogens and is eradication successful?
  44. The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry
  45. Diagnosis and management of primary ciliary dyskinesia
  46. Diagnosis of cystic fibrosis in London and South East England before and after the introduction of newborn screening
  47. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening
  48. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF
  49. Lung Clearance Index at 4 Years Predicts Subsequent Lung Function in Children with Cystic Fibrosis
  50. Non-cystic fibrosis bronchiectasis: its diagnosis and management
  51. Growth in children with cystic fibrosis‐related diabetes
  52. Lung Function from Infancy to the Preschool Years after Clinical Diagnosis of Cystic Fibrosis
  53. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests
  54. A comparison of the prevalence of urinary incontinence in girls with cystic fibrosis, asthma, and healthy controls
  55. Growth and lung function in Asian patients with cystic fibrosis
  56. Relative Ability of Full and Partial Forced Expiratory Maneuvers to Identify Diminished Airway Function in Infants with Cystic Fibrosis
  57. Airway function in infants newly diagnosed with cystic fibrosis
  58. Reproductive health in males with cystic fibrosis: Knowledge, attitudes, and experience of patients and parents
  59. An evaluation of two aerosol delivery systems for rhDNase